Historic FDI Nod in Indian Pharma

Suven's potential 90.1% foreign investment surpasses the 74% FDI limit in brownfield projects.

Suven Pharma Gets Greenlight for Rs 9,589 Cr FDI

Cabinet approves Berhyanda's investment for a potential 76.1% stake in Suven Pharma.

Advent Funds' Strategic Move in Suven Pharma

Cyprus-based Berhyanda, managed by Advent Funds, is set to acquire a majority stake.

Rigorous Evaluation of Suven Pharma Deal

Thorough scrutiny by relevant departments, RBI, and SEBI leads to approval.

Suven Pharma's Market Response

Shares surge over 6% post-CCEA approval, trading higher at Rs 542.75.

Growth Trajectory with Advent's Investment

Advent's entry signifies a transformative phase for Suven Pharma's strategic positioning.